Market Exclusive

ADVAXIS, INC. (NASDAQ:ADXS) Files An 8-K Results of Operations and Financial Condition

ADVAXIS, INC. (NASDAQ:ADXS) Files An 8-K Results of Operations and Financial ConditionItem 2.02

Results of Operations and Financial Condition.

On June 7, 2018, Advaxis, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended April 30, 2018 and providing a business update. The Company also hosted an investor conference call on June 7, 2018, during which the Company provided a business update and a brief overview of its financial results. A copy of such press release is being furnished as Exhibit 99.1 to this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished as part of this report:

Advaxis, Inc. ExhibitEX-99.1 2 ex99-1.htm     Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results   Annual cash burn will be reduced to approximately $50 million from approximately $80 million through a combination of portfolio rationalization and headcount reduction   Conference call begins today at 11:00 a.m. Eastern time   PRINCETON,…To view the full exhibit click here
About ADVAXIS, INC. (NASDAQ:ADXS)
Advaxis, Inc. is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company’s immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers.

Exit mobile version